drugset / Trial / NCT00707252

Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

NCT00707252

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to study if the addition of the green tea extract, Polyphenon E, to Erlotinib is safe and if it has potential to improve outcomes in second line therapy for Advanced Stage IIIb/IV Non-small cell lung cancer.

Timeline

Start
2008-01
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Sinecatechins Unknown 200 mg
Subject Sinecatechins Unknown 400 mg
Subject Sinecatechins Unknown 800 mg
Background Erlotinib Small molecule 150 mg Oral